摘要
目的:探讨RhoC蛋白在正常卵巢组织、良性上皮性卵巢肿瘤、交界性上皮性卵巢肿瘤和卵巢上皮性癌组织中的表达,及其与卵巢上皮性癌发生、发展及生物学行为的相关性。方法:采用链霉菌抗生物素蛋白-过氧化酶(SP)免疫组织化学方法检测19例正常卵巢组织、20例卵巢良性上皮性肿瘤、27例卵巢交界性上皮性肿瘤及45例卵巢上皮性癌中RhoC蛋白的表达情况,并分析其与各临床病理特征的关系。结果:RhoC蛋白在正常卵巢组织及良性上皮性卵巢肿瘤中的表达均为阴性;RhoC蛋白在交界性上皮性卵巢肿瘤及卵巢上皮性癌中阳性表达率分别为25.93%和26.67%,与正常卵巢组织及卵巢良性上皮性肿瘤相比,差异有显著性(P<0.05);卵巢上皮性癌与交界性卵巢肿瘤表达比较,差异无显著性(P>0.05)。RhoC蛋白的阳性表达率与临床分期及组织学分级有关(P<0.05),与卵巢上皮性癌病理类型无关(P>0.05);卵巢上皮性癌临床分期越晚,组织学分级越高,分化越差,RhoC蛋白的表达水平越高。结论:RhoC蛋白在卵巢上皮性癌的发生、发展中起着重要的作用,可成为判断卵巢上皮性肿瘤由良性向恶性转化的标志,对其检测可用于判断卵巢肿瘤的恶性程度,并可用于判断预后。
Objective: To investigate the expression of RhoC protein in normal ovarian tissues, benign ovarian epithelial tumors, borderline malignancies and ovarian epithelial carcinoma, and to explore the correlation between the expression of RhoC protein and occurrence, progression and biological behavior of ovarian epithelial carcinoma. Methods: The expression of RhoC protein was detected by immunohistochemistrical SP method in 19 samples of normal ovarian tissues, 20 samples of ovarian benign epithelial tumor, 27 samples of ovarian epithelial borderline tumor and 45 samples of ovarian epithelial carcinoma. The relationship between RhoC protein and pathological feature was analyzed. Results: RhoC was absent in both normal ovarian tissues and benign epithelial tumors. The positive rates of RhoC protein expression in borderline tumors and o- varian cancer were 25.93% and 26.67%, respectively, significantly higher than in normal ovarian tissues and benign ovarian epithelial tumors (P〈0.05). No significant difference was found in RhoC protein expression between ovarian carcinoma and borderline tumors (P〉0.05). The expression of RhoC protein was correlated with clinical stage and histological differentiation, but not associated with pathological type (P〉0.05). Tissues from ovarian carcinoma of late stage and poor differentiation presented with increased RhoC expression. Conclusion: RhoC protein may play an important role in the occurrence and development of ovarian cancer. The detection of RhoC protein expression may be helpful in predicting the malignant degree of ovarian tumor and its prognosis.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2008年第20期1184-1187,共4页
Chinese Journal of Clinical Oncology
基金
长春市科技攻关计划资助(编号:06GG95)